Related Experiment Video

Updated: May 21, 2026

Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs
11:00

Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs

Published on: June 12, 2018

MicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1

Hong-Can Zhu1, Li-Mei Wang, Miao Wang

  • 1Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, PR China. zhuhongcan001@163.com

Brain Research Bulletin
|June 23, 2012
PubMed

Insights

MicroRNA-195 (miR-195) reduces amyloid-beta (Aβ) production by targeting beta-site APP cleaving enzyme 1 (BACE1). This finding suggests miR-195 as a potential therapeutic strategy for Alzheimer's disease (AD).

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Alzheimer's disease (AD) is a neurodegenerative disorder marked by amyloid-beta (Aβ) plaques and neurofibrillary tangles.
  • MicroRNAs (miRNAs) are implicated in regulating Aβ production, with lower levels observed in AD patients and models.
  • The specific role of miR-195 in Aβ formation warrants investigation.

Purpose of the Study:

  • To investigate the role of miR-195 in the regulation of amyloid-beta (Aβ) production.
  • To determine if miR-195 directly targets beta-site APP cleaving enzyme 1 (BACE1).
  • To explore the therapeutic potential of miR-195 for Alzheimer's disease (AD).

Main Methods:

  • Bioinformatics analysis to predict miR-195 binding sites in the BACE1 3'-UTR.
  • Luciferase assay in HEK293 cells to confirm BACE1 as a miR-195 target.
  • In vitro experiments involving miR-195 overexpression and inhibition in neuronal cell lines (N2a/WT and N2a/APP) to assess BACE1 and Aβ levels.

Main Results:

  • miR-195 levels were inversely correlated with BACE1 protein levels in SAMP8 mice.
  • miR-195 was confirmed to bind to the 3'-UTR of BACE1.
  • Overexpression of miR-195 reduced BACE1 protein and Aβ levels, while inhibition increased them.

Conclusions:

  • miR-195 downregulates Aβ production by inhibiting BACE1 translation.
  • miR-195 demonstrates potential as a novel therapeutic target for Alzheimer's disease (AD).

More Related Videos

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease09:33

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...